An affiliate marketer of Tokyo-structured Astellas Pharma Inc.

.. Agensys, Seattle Genetics to co-develop second antibody-drug conjugate for multiple solid tumors Seattle Genetics, Inc. and Agensys, Inc., an affiliate marketer of Tokyo-structured Astellas Pharma Inc. , today announced that Seattle Genetics has exercised a choice to co-develop a second antibody-drug conjugate under the businesses’ existing ADC collaboration agreement. The ADC, referred to as ASG-22Me personally , targets the Nectin-4 antigen, which is usually expressed on multiple solid tumors. During the first one fourth of 2011, Agensys submitted an investigational new medication software to the U.S. Food and Medication Administration for a phase I trial of ASG-22ME.This content was reprinted from with permission from the Henry J. Kaiser Family members Foundation. Kaiser Health Information, an independent news service editorially, is an application of the Kaiser Family members Foundation, a nonpartisan health care policy research business unaffiliated with Kaiser Permanente.. Actavis obtains final authorization from FDA for generic Subutex Actavis plc today announced that it offers received final acceptance from the U.S. Actavis intends to begin shipping its product shortly.S.